Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 17.20 as of 2026-10-06T16:08:17.462Z.
Consensus retrieved: 2026-10-06T13:12:54.665Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:08:17.462Z.
Quote observation: 2026-10-06T16:04:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd20ca937d8098c5f852a943e32d80916ba0700dfdb9ded1ca0835b20f97e071
Forward PE Ratio (17.20) = Dated Quote Price ($8.21) / Consensus Forward EPS ($0.48)
FORWARD PE RATIO
17.20
SECTOR MEDIAN · HEALTHCARE
19.64
median of 174 covered companies
CURRENT VS SECTOR MEDIAN
-12.45%
vs the sector median at left
Kamada Ltd.
Market Cap
$473.96M
Forward PE Ratio
17.20
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Kamada Ltd. (KMDA) | $473.96M | 17.20 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $474.25M | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $474.87M | N/A |
| Cerus Corporation (CERS)vs › | $472.58M | N/A |
| Arvinas, Inc. (ARVN)vs › | $479.06M | N/A |
| NRC Health (NRC)vs › | $462.12M | 23.30 |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.87M | 25.17 |
| Evolus, Inc. (EOLS)vs › | $490.62M | N/A |
| Oculis Holding AG (OCS)vs › | $496.23M | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $450.48M | N/A |
Trailing P/E
21.7
reported TTM EPS
Forward P/E
17.2
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.48 implies +26.3% EPS growth vs the reported trailing $0.38.
At the dated quote price of $8.21, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.48 | $0.42 – $0.52 | 3 | 17.2x |
| 2027-12-31 | $0.58 | $0.46 – $0.71 | 3 | 14.2x |
| 2028-12-31 | $0.65 | $0.64 – $0.66 | 1 | 12.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
